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expiry of the original brand, from a third payer’s perspective,
based on the alendronate case. METHODS: The Belgian trade
name for alendronate is Fosamax® (patent expiry: April 2008).
The basis for reimbursement (reference price) for generics is set
by law at minus 30%. The originator company introduced
Fosavance® (ﬁxed combination with vitamin D—patent expiry:
2018) in July 2006. Using registered consumption data from
RIZIV, the evolution of the monthly expenses for alendronates
was considered and expected annual expenses were estimated
with or without the reimbursement of Fosavance®. RESULTS:
The monthly expenses for Fosamax® decreased from €2.7 Mio
prior to the reimbursement of Fosavance® to €1.4 M by July
2007. Simultaneously the expenses for Fosavance® increased to
€1.4 M. Only 52% of the market (in value) is left for generic
competition. The monthly opportunity savings are estimated to
be 30% of €1.4M (€0.52 M) instead of 30% of €2.7 M
(€0.81 M). The opportunity loss is therefore €3.5 M per year
assuming constant market value (137,500 patients treated with
alendronates in 2006). CONCLUSIONS: The alendronate
patent expiry and generic competition would theoretically have
generated an economy of 30% on the entire alendronate
market. The switch to the patent-protected ﬁxed combination
however shelters a substantial part of this market from generic
competition and from the effects of the off-patent reimburse-
ment policy. Therefore, this ‘life cycle management’ technique
jeopardizes the release of ﬁnancial resources and the creation of
budget headroom, essential for ﬁnancing the access to new
and/or innovative medicines. It should be considered as an
opportunity ‘lost’.
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OBJECTIVES: The Hungarian goverment allocates signiﬁcant
investment budget for hospital development between 2008–
2013. A cost-beneﬁt model was developed to assess the social
beneﬁt of public health care investments. We present the results
for a planned investment in a large district hospital with 1586
beds. METHODS: We considered the following long-term social
and ﬁnancial beneﬁts: 1) QALY gain and incremental costs from
new services; 2) cost savings and QALY gain from simpliﬁed
patient routes and reduced postoperative complication; 3)
improved technical efﬁciency of operation (e.g. matrix organiza-
tion); and 4) reduction of ﬁxed costs. Inncremental costs and
beneﬁts are calculated over a 15 year period. We employed 8%
discount rate for costs and 5% for QALYs. Health beneﬁts were
translated to monetary terms by assuming 40,000€/QALY gain
coversion rate. 250 HUF/1€ exchange rate was used in the
model. RESULTS: Our model estimated €8.1 million ﬁnancial
and €43.7 million social beneﬁt over 15 years from the €49.5
million investment. The Net Present Value of the hospital devel-
opment project is €7.5 million (including the remaining value of
assets after 15 years). The investment potentially improves the
sustainabilty of the hospital operation, as the annual net ﬁnancial
balance exceeds the annual cost of depriciation by €800,000.
CONCLUSIONS: Cost-beneﬁt analysis of public investment
projects improves the allocative efﬁciency of scarce resources.
Our model can assess the return on investemnt by capturing
long-term social and ﬁnancial beneﬁts and also the sustainability
of hospital operation. Prospective validation of the model is
necessary.
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OBJECTIVES: To describe the effect of patient’s morbidity load
in relation to resource utilization in Primary Care (measured by
pharmacy cost and visits) trough the retrospective application of
ACG in 23 Primary Care Health Centres from three Spanish
regions. METHODS: Multicentre, retrospective study based on
data from electronic records of patients seeking care during 2005
in the autonomous regions of Aragon, Balearics and Catalonia.
Principal measurements: universal variables (age, sex, health
service-family practice/paediatrics), variables of morbidity
(resource utilization bands [RUB]) and dependent variables
(visits, episodes and pharmacy cost). The ACG case-mix System
software (version 7.0; n = 106) classiﬁed subjects into a single
category for a given annual resource consumption. A log trans-
formation of dependent variables was carried out to reduce skew
ness of the distribution and make it close to normal. Statistical
software: SPSSWIN, p < 0.05. RESULTS: Study population:
286,450 (Aragon: 49.3%; Balearics: 23.2%; Catalonia: 27.5%),
annual coverage: 75.5% of the population, patient’s mean age:
42.9  23.6 years, percentage of female patients: 54.1%, mean
number of consultations: 7.3  7.1; 6.6  7.0 and 8.0  8.1
correspondingly, p < 0.001. Patient’s case-mix: 55.0% of the
study population was grouped into 10 ACG. A high variability
was observed among regions with differences in the average
values of RUB (2.9  0.8; 2.3  0.8; 2.4  0.8) and pharmacy
cost (€361.67; €242.01; 290.89), p < 0.001. The explanatory
power of the ACG classiﬁcation system was 30.7% (Ln: 41.2%)
for visits, 87.6% (Ln: 87.1%) for episodes and 21.3% (Ln:
39.9%) for pharmacy cost, p < 0.001. CONCLUSIONS: The
fact that patient’s morbidity load is adequately correlated with
attended consultations and pharmacy cost reinforces the appro-
priateness of the ACG system when associating clinical and eco-
nomic information from health care centers in Primary Care. In
consequence, case-mix adjustment must be considered for clini-
cal decision-making and ﬁnancial management in Primary Care.
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OBJECTIVES: Financial protection of the afﬁliated workers to
the Social Security Mexican Institute (IMSS) is one of its core
functions; however it also generates outlays to the health system.
This study estimates the associated cost to additional sick leave
days due to medical causes and/or due to inefﬁciencies on the
system. METHODS: A cost study was made from the perspective
of the institution through a prospective cohort of male and
female patients to whom it was prescribed temporal sick leave
days due to diseases not related to the work environment (general
disease), a follow-up was scheduled until their return to their
work place and the cost of medical attention was calculated; this
included ambulatory consult, drugs, lab exams, urgency service
assistance, surgery, hospital time and payment under the concept
of sick leave. All patients must have an estimation of the prob-
able number of recovery days, those who required additional
days were identiﬁed and the causes that triggered a longer lapse.
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The additional costs for additional sick leave days were calcu-
lated. Signiﬁcant statistical differences were established in the
cost through a Mann Witney’s U test. RESULTS: A total of 1019
patients were included with an average age of 37  11 years,
49% of which were men. These patients were prescribed with
12,273 sick leave days, the average per patient was 12 days (4–93
days). The total cost of the attention of this patients was of US$
781,806.76. 17.9% of the patients had additional sick leave
days. The average cost of the medical attention of the patients
without additional days was of US$773.74  1135.01 and of the
patients with additional days was of US$737.74  960.38, the
differences were statistically signiﬁcant (p < 0.005). CONCLU-
SIONS: The additional sick leave days have not a signiﬁcant
impact in the attention cost of the patients afﬁliated to the IMSS.
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OBJECTIVES: To examine pharmaceutical expenditure growth
during the years 1980–2006 in Greece in relation to major phar-
maceutical policy changes. METHODS: Data from the OECD
Healthdata database and the National Statistical Service of
Greece were used. Pharmaceutical expenditure data were
deﬂated using the Greek Pharmaceutical Price Index (2005 =
100). Due to the recent revision of the Greek GDP from the
Greek National Statistical Service and Eurostat, data were
divided in two time series, from 1980 to1999 (data not revised)
and from 2000 to 2006 (revised data). Deﬂated data are available
for 1982–1999 and 2000–2006. RESULTS: Pharmaceutical
expenditure mean annual growth rate (MAGR) during the period
1980–1999 was 17.3% and 10.5% from 2000 to 2006. Real
pharmaceutical expenditure MAGR was 9.8% for 1982–1999
and 9.7% for 2000–2006. Pharmaceutical expenditure decreased
by 7.7% from 1997 to 1998 and continued to increase the
following year. Pharmaceutical expenditure growth rates were
higher than the Pharmaceutical Price Index growth rates. Public
pharmaceutical expenditure increased at higher rates compared
to private pharmaceutical expenditure. CONCLUSIONS: Phar-
maceutical expenditure in real values has been constantly rising
during the study period. Pharmaceutical policy reforms intro-
duced in order to contain pharmaceutical expenditure growth
such as the introduction of a positive reimbursement list (1998)
and the pricing of pharmaceuticals at the lowest price of EU
countries (1997) had limited effect. In 2005 a new pricing system
was introduced based on the average of the three lowest EU
prices while in 2006 the positive list was abolished. in relation to
major pharmaceutical policy changes.
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OBJECTIVES: Quality improvement is one mechanism for
reducing health care expenditure. Therefore there is a need for
ranking providers according to their performance. By character-
izing hospital quality by our previously validated composite
measure, to compare the high vs low quality hosptals and their
associated outlier payments. METHODS: Using the national
Medicare claims database for 2006, we examined outlier pay-
ments in patients undergoing coronary artery bypass grafting
(CABG) (n = 104,329). We then categorized hospitals perform-
ing these procedures according to their outlier payment rates.
Using multiple logistic regression, we explored the relationships
between hospital outlier payment rates and hospital quality,
as reﬂected by previously validated composite quality score.
RESULTS: The proportion of patients associated with outlier
payments was 9% (CABG). Average outlier payments were con-
siderable: $19,000 per patient, costing Medicare more than $175
million. Risk adjusted outlier rates for 5-Star Hospitals was only
6.7% whereas low quality hospitals had outlier rates have more
than 11%. CONCLUSIONS: Outlier payments in CABG are an
important component of medical costs with inpatient surgery.
Although persistent differences in billing and accounting prac-
tices maybe an important factor, this differences explained in part
by quality.
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OBJECTIVES: The objective is to obtain a perspective on the
allocation efﬁciency for the local level, and for the system as a
whole. In this direction, data of health ﬁnancing was analyzed
considering its correlation with demand and supply indicators,
and an epidemiological index was designed on the basis of mor-
bidity and mortality. Based on its allocation efﬁciency, a munici-
pality was identiﬁed as a “pattern”, and the performance of each
municipality and the system as a whole was analyzed in front of
it. METHODS: The present study analyzes, on one hand, the
inﬂuence of the indicators of demand and needs in the ﬁnancing
of health in Buenos Aires Province municipalities and, on the
other one, proposes a way to measure the intermunicipal ﬁnanc-
ing gaps. For this, a municipal pattern of efﬁcency is selected
considering the municipality with best results according to health
ﬁnancing. RESULTS: Results show a high correlation between
municipal health expenditures and supply indicators (like hospi-
tal beds), with little incidence of morbidity and mortality, dis-
playing a dissociation between health expenditures and sanitary
needs. In 24 of the 117 municipalities with available information,
health expenditures present as higher than expected considering
their epidemiological proﬁle, whereas the other 93 would be
below their ﬁnancial requirements. In global terms, the system
shows deﬁcit of 1,126 million of Argentinean Pesos (53% supe-
rior to the present budget), with deep gaps among municipalities.
Also, the dispersion in the patterns of health ﬁnancing is high,
reaching a relation of 4.15:1. CONCLUSIONS: The gap between
municipalities requires a cautious analysis in order to identify
successful models of management, that could be replicated to
diminish the system inefﬁciency. Finally, a debate around the
criteria that condition the transference of coparticipables funds
to municipalities is proposed, in order to obtain a greater asso-
ciation between health expenditures and results, with a smaller
transference of risk towards the local levels.
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OBJECTIVES: To identify preventive interventions, not system-
atically implemented, that may be cost-effective in reducing the
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